Clinical Trial Detail

NCT ID NCT02556931
Title Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sidney Kimmel Comprehensive Cancer Center
Indications

myeloproliferative neoplasm

CLL/SLL

prolymphocytic leukemia

myelodysplastic syndrome

plasma cell neoplasm

chronic myeloid leukemia

Therapies

Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus

Age Groups: adult child senior

No variant requirements are available.